More big names in cannabis are switching to psychedelics.
Greg Engel, former CEO of Tilray TLRY and Organigram Holdings OGI has become the latest cannabis veteran to join the psychedelics industry, taking on the role of director at Clairvoyant Therapeutics.
Clairvoyant is a Canadian biotech company focused on the clinical validation of psilocybin in the Canadian, U.K. and European Union markets.
The company is currently on the road to receiving approval to begin a phase 2 trial on psilocybin for the treatment of alcohol use disorder.
Previously, Engel also served as the Canadian general manager for Forest Laboratories, now part of AbbVie ABBV and Encysive, now part of Pfizer PFE.
Engel is not the first high-profile cannabis executive to join a psychedelics company.
Bruce Linton, former CEO and co-founder of Canopy Growth CGC, recently stepped down from the board of MindMed MNMD after two years with the psychedelics unicorn.
Vic Neufeld, former CEO of Aphria Inc. APHA currently serves as executive chairman of Havn Life Sciences HAVN HAVLF, a company working to develop a supply chain around natural psychedelic compounds.
Photo: Image extracted from Youtube.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.